“But we do think that the volume growth will be at meaningfully lower levels than what we've seen year-to-date.”

In context

“da had very strong growth this year. And I think a big part of that has been just a direct result of the commercial effort and attention that we've put on it where we've seen real growth in the diagnosis rate and new patient starts. So new patient starts are up about 61% versus last year. And they're up about 3% quarter-over-quarter as well, and we're also improving compliance rates significantly with existing patients. For the market, there's a lot of patients, nearly half that remain diagnosed. So there's significant opportunity there. We will have tailwinds as we go forward. So we continue to put attention on this, and that's going to be largely increased diagnosis education, the prescriber rate that we're growing as well as affordability conditions and we've turned the page into 2025. But we do think that the volume growth will be at meaningfully lower levels than what we've seen year-to-date. And a big part of that is obviously headwinds we're going to see from the changing market landscape, where we will have new competitive entrants that will impact new patient starts as well as potential switching of existing patients onto some of these options. So those are some of the puts and takes on Vinda. IRA will be a piece of that as well as Dave mentioned, and we'll have more to share about '25 specifics when we give guidance. Operator: We'll take our last question from Mohit Bansal with Wells Fargo. Mohit Bansal: And first of all, congrats on a phenomenal hire in [indiscernible]. So maybe like taking the step back, can you comment something about ABRYSVO if there was any stocking this quarter? This particular market is a lot of like stocking driven in fourth and first quarter. So”